Muhlenkamp & Co. Inc. Trims Position in Pfizer Inc. (NYSE:PFE)

Muhlenkamp & Co. Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,014 shares of the biopharmaceutical company’s stock after selling 675 shares during the quarter. Muhlenkamp & Co. Inc.’s holdings in Pfizer were worth $980,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of PFE. TFO TDC LLC purchased a new stake in Pfizer during the 4th quarter worth $37,000. Wealthcare Capital Management LLC grew its stake in shares of Pfizer by 61.2% in the fourth quarter. Wealthcare Capital Management LLC now owns 1,069 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 406 shares in the last quarter. Stonebridge Financial Planning Group LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $55,000. Cardinal Capital Management Inc. raised its holdings in shares of Pfizer by 45.0% during the 4th quarter. Cardinal Capital Management Inc. now owns 1,450 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 450 shares during the period. Finally, ICW Investment Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $58,000. Institutional investors and hedge funds own 71.63% of the company’s stock.

Shares of PFE traded down $0.85 during trading on Friday, reaching $30.90. The company’s stock had a trading volume of 36,321,685 shares, compared to its average volume of 32,875,543. The company has a market cap of $165.04 billion, a price-to-earnings ratio of 10.77, a P/E/G ratio of 2.40 and a beta of 0.69. The company has a quick ratio of 0.66, a current ratio of 0.88 and a debt-to-equity ratio of 0.57. The company has a fifty day moving average of $34.16 and a two-hundred day moving average of $36.92. Pfizer Inc. has a twelve month low of $27.88 and a twelve month high of $44.56.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 28th. The biopharmaceutical company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.02). The company had revenue of $12.69 billion during the quarter, compared to analyst estimates of $12.73 billion. Pfizer had a net margin of 31.44% and a return on equity of 27.01%. The company’s revenue was down 9.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.64 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.8 EPS for the current fiscal year.

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, January 30th. The stock was acquired at an average cost of $37.15 per share, with a total value of $37,150.00. Following the acquisition, the director now owns 4,000 shares of the company’s stock, valued at approximately $148,600. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Pfizer Inc acquired 312,500 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were acquired at an average cost of $16.00 per share, with a total value of $5,000,000.00. The disclosure for this purchase can be found here. Company insiders own 0.08% of the company’s stock.

A number of equities analysts have weighed in on the company. Cantor Fitzgerald restated a “buy” rating and issued a $53.00 price target on shares of Pfizer in a report on Thursday, March 19th. Barclays assumed coverage on shares of Pfizer in a research note on Thursday, February 27th. They issued an “equal weight” rating and a $36.00 target price for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $37.00 price target on shares of Pfizer in a report on Tuesday, January 28th. Royal Bank of Canada lowered their price target on shares of Pfizer from $46.00 to $44.00 and set an “outperform” rating for the company in a report on Friday. Finally, Standpoint Research raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Eight analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Pfizer has an average rating of “Buy” and an average price target of $41.19.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: What are the benefits of a balanced fund?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.